
Anixa Biosciences Inc
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Anixa Biosciences is a biotechnology company developing therapeutics in the areas of cancer treatment and diagnostics, including chimeric antigen receptor (CAR) T-cell immunotherapy approaches for ovarian cancer and other solid tumors. It also works on early cancer detection technologies and vaccine research programs, often through collaborations with academic and research institutions.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| KUMAR AMITChief Executive Officer | Buy | $22K | 8,000at $2.72 | Oct 22, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ANIX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.